Laura Adams, Senior Advisor at the National Academy of Medicine (NAM), provides strategic advising for the Science and Technology portfolio of the Leadership Consortium and leads the NAM’s Artificial Intelligence Code of Conduct (AICC) national initiative. Her expertise is digital health, the science of improvement, and human-centered care. Laura serves on the boards of Boston-based T2 Biosystems and TMA Precision Health; the Steering Committee of the Coalition for Health AI (CHAI); and the Oversight Council for the Massachusetts Center for Health Information and Analysis. She is a strategic advisor for Inflammatix, a Burlingame, CA-based biotech company specializing in transcriptomics/host immune response diagnostics.
Laura chaired the Institute of Medicine’s (IOM) Planning Committee for the “Digital Infrastructure for Population Health and a Learning Healthcare System” initiative. She is recognized as a strategic leader of large scale multisectoral initiatives with a deep experience in and understanding of the complex U.S. health care industry, including how the components function and interact.
Laura was among the first to bring the principles of healthcare quality improvement to the Middle East, in conjunction with Donald Berwick, MD and the Harvard Institute for Social and Economic Policy in the Middle East. She served as Institute for Healthcare Improvement (IHI) faculty at the inaugural IHI Middle East Forum on Quality Improvement in Healthcare in Doha, Qatar.
Laura was founding President and CEO of the Rhode Island Quality Institute (RIQI), Rhode Island’s statewide health information exchange. Under her leadership, RIQI won the National Council for Community Behavioral Health Excellence Award for Impact in serving those with behavioral health and substance abuse challenges. RIQI was the recipient of the national 2018 Healthcare Informatics Innovation Award for impact on the opioid crisis; and was a top finalist for the 2018 New England Business Innovation award.